Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
01/2003
01/02/2003EP0628074B1 In vitro activation of cytotoxic t cells
01/01/2003CN1388126A 吡咯并三嗪和嘧啶化合物 Pyrrolo-triazine and pyrimidine compounds
01/01/2003CN1387886A Chinese medicine prepn for treating lupus erythematosus
01/01/2003CN1387876A Clover extract, composition with the extract and their application in animal health
01/01/2003CN1387855A Licorice polysaccharide powder injection
01/01/2003CN1387847A Lefunomide plaster and its prepn
01/01/2003CN1387845A Medicinal composition for treating autoimmune disease
01/01/2003CN1097463C Method for preparing medicinal moxibustion materials extractive preparation for electrical moxibustion therapy
01/01/2003CN1097459C Diazepino-indoles as phosphodiesterase IV inhibitors
12/2002
12/31/2002USRE37952 Grb3-3 cDNA and polypeptides
12/31/2002US6500959 Pyrrolidine derivatives and processes for preparing same
12/31/2002US6500864 Disulfide derivatives useful for treating allergic diseases
12/31/2002US6500863 Interleukin binding inhibitors such as n-(2-hydroxyl-3-amino sulfonyl-4-chlorophenyl)-n'-(2-bromophenyl)urea, used for prophylaxis of chemokine mediated diseases
12/31/2002US6500856 For therapy of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators
12/31/2002US6500845 Activating cytokine release using immunosuppressants such as 2-(3-methyl-2-oxo-piperidin-3-yl)-benzo(d)isoselenazol-3-one, racemic mixtures or isomers having dimensional stability, prepared in the presence of reducing agent
12/31/2002US6500839 CRF receptor antagonists and methods relating thereto
12/31/2002US6500823 Energy deficiency of the cell caused by parp inhibition, in diabetes complications, in oxygen deficient status of the heart and brain, in neurodegenerative diseases, in the treatment of autoimmune and/or viral diseases
12/31/2002US6500811 Prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved; these include degenerative joint disorders such as osteoarthroses and disorders of connective tissue
12/31/2002US6500804 Administering a dipeptidyl aminopeptidase effector which is selected from the group consisting of n-(n-substituted glycyl)2-cyanopyrrolidones, n-aminoacyl thiazolidines, n-aminoacyl pyrrolidines
12/31/2002US6500642 Mammalian cdna which encodes a mammalian mapop-3. it also provides for the use of the cdna, fragments, complements, and variants thereof and of the encoded protein, portions thereof and antibodies thereto for diagnosis and treatment of breast
12/31/2002US6500641 Expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element,
12/31/2002US6500467 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
12/31/2002US6500432 Method to enhance an immune response of nucleic acid vaccination
12/31/2002US6500424 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
12/31/2002US6500423 Probiotic composition comprising viable escherichia coli strain bu-230-98 atcc deposit no. 20226 (dsm 12799) and a formulation for maintaining viability of said escherichia coli strain
12/31/2002US6500422 Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)
12/31/2002US6500418 Stimulating neutrophil function to treat inflammatory bowel disease
12/31/2002CA2097732C Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus
12/27/2002WO2002103031A2 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002WO2002102853A2 Cd4-specific antibody trx1 and uses therefor
12/27/2002WO2002102852A2 Modified cd8 molecule, nucleic acid encoding said molecule, and their therapeut ic use
12/27/2002WO2002102840A2 Multiners of class i major histocompatibility complexes cantaining modified beta2-microglobulin proteins
12/27/2002WO2002102800A1 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
12/27/2002WO2002102787A2 Novel sulfonic acid derivatives
12/27/2002WO2002102778A1 Phenylpyridine carbonyl piperazine derivative
12/27/2002WO2002102775A1 Derivatives of 3-phenyl-n-(2- (4-benzyl) piperidin-1-yl)-ethyl)-acrylamid with ccr-3 receptor antagonistic activity for use in the treatment of inflammations and allergic conditions
12/27/2002WO2002102771A1 Tryptase inhibitors
12/27/2002WO2002102407A1 Therapeutical vaccination
12/27/2002WO2002102403A1 Mucosal repair by tff dimer peptides
12/27/2002WO2002102397A1 Use of an extract of the root of balloon-flower for preventing and treating a degenerative brain disease or for enhancing memory
12/27/2002WO2002102395A1 Nerium oleander extract, compositions containing the nerium oleander l. extract and a method of preparation of this extract
12/27/2002WO2002102394A2 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
12/27/2002WO2002102363A1 Biological response modifier composition and uses thereof
12/27/2002WO2002102344A2 No-synthase inhibitor and use thereof
12/27/2002WO2002102343A1 Ascorbyl 2-hexadecanoate as a no-synthase inhibitor
12/27/2002WO2002102320A2 Fce fusion proteins for treatment of allergy and asthma
12/27/2002WO2002102315A2 QUINAZOLINE AND PYRIDO[2,3-d]PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7
12/27/2002WO2002102314A2 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002WO2002102313A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002WO2002102310A2 Proteins associated with cell growth, differentiation, and death
12/27/2002WO2002102307A2 Nucleoside vaccine adjuvants
12/27/2002WO2002087626A9 Pharmaceutical compositions comprising dendritic cells for immunotherapy of autoimmune disease and treatment methods using the same
12/27/2002WO2002083696A3 Novel cyclo azaphospha hydrocarbons
12/27/2002WO2002076946A3 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
12/27/2002WO2002074776A3 Highly purified and crystalline form of harringtonine
12/27/2002WO2002072077A3 Use of amino acids, amino acid analogues, sugar phosphates and sugar phosphate analogues for treatment of tumors, treatment of sepsis and immunosuppression
12/27/2002WO2002062335A3 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
12/27/2002WO2002060922A3 Epoxyvibsanin b
12/27/2002WO2002056907A3 Molecular antigen array presenting amyloid beta
12/27/2002WO2002055099A3 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
12/27/2002WO2002055087B1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
12/27/2002WO2002053142A3 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
12/27/2002WO2002045746A3 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
12/27/2002WO2002018445A8 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
12/27/2002WO2002012467A3 Drug metabolizing enzymes
12/27/2002WO2002004514A8 Compositions and methods for the therapy and diagnosis of lung cancer
12/27/2002WO2001087935A9 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
12/27/2002WO2001085986A3 Phosphatidyl inositol 3-kinase delta binding partner
12/27/2002WO2001079300A9 Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor
12/27/2002WO2001074903A9 Cd20/ige-receptor like molecules and uses thereof
12/27/2002CA2489019A1 Therapeutical vaccination
12/27/2002CA2455387A1 Fce fusion proteins for treatment of allergy and asthma
12/27/2002CA2450936A1 Purine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450934A1 Pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450809A1 Methods for detecting and treating the early onset of aging-related conditions
12/27/2002CA2450724A1 Quinazoline and pyrido¬2,3-d|pyrimidine inhibitors of phosphodiesterase (pde) 7
12/27/2002CA2450700A1 Trx1 antibody and uses therefor
12/27/2002CA2450659A1 Tryptase inhibitors
12/27/2002CA2450067A1 Proteins associated with cell growth, differentiation, and death
12/27/2002CA2449898A1 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
12/27/2002CA2448298A1 Phenylpyridine carbonyl piperazine derivative
12/27/2002CA2443630A1 Nerium oleander extract, compositions containing the nerium oleander l. extract and a method of preparation of this extract
12/26/2002US20020198509 Intradermal delivery of vaccines and gene therapeutic agents via microcannula
12/26/2002US20020198407 Antiallergy agents and bronchodilators
12/26/2002US20020198379 Active compound from a sponge
12/26/2002US20020198367 DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof
12/26/2002US20020198251 Substituted 2-dialkylaminoalkylbiphenyl derivatives
12/26/2002US20020198242 Administering to an animal an effective dose of atleast an enzyme Dipeptidyl Peptidase (DP IV) enzyme activity effector to increase the capacity of insulin producing cells
12/26/2002US20020198237 2,5-substituted imidazole compounds useful as histamine H3 receptor mediators
12/26/2002US20020198208 Medicinal preparation and process for manufacturing thereof
12/26/2002US20020198198 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
12/26/2002US20020198190 Tetracyclic 1,2,3,4,5,6- hexahydroazepino-(4,5-b)indole derivatives having a ring connecting position 6 (N-6) and position 7 (C-7); treating or preventing a disease or disorder of the central nervous system in a mammal
12/26/2002US20020198173 Viricides for treating HIV and hepatitis virus
12/26/2002US20020198143 B7-like polynucleotides, polypeptides, and antibodies
12/26/2002US20020198142 Integrin inhibitors, for the treatment of disorders caused by implants, defects, inflammations and of osteolytic disorders such as osteoporosis, thrombosis, cardiac infarct and arteriosclerosis
12/26/2002US20020197599 Novel adjuvants and copolymer compositions
12/26/2002US20020197270 Immunogenic compositions for induction of anti-tumor immunity
12/26/2002US20020197269 Pharmaceutical composition for immunomodulation and preparation of vaccines
12/26/2002US20020197256 Combination therapy
12/26/2002US20020197248 Method for treating a LFA-1-mediated disorder
1 ... 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 ... 1172